- Email: [email protected]
A message from the New Editor-in-Chief
Drug Resistance Updates 13 (2010) 1
Contents lists available at ScienceDirect
Drug Resistance Updates journal homepage: www.elsevier.com/locate/drup
Editorial
A message from the New Editor-in-Chief Drug Resistance Updates—The past and the future
Twelve years have passed since Drug Resistance Updates was founded. During this period the journal has maintained its original mission: to critically review and analyze chemotherapeutic resistance in infectious diseases and cancer; to integrate recent developments in both basic research and clinical medicine; and to highlight innovative strategies for current and emerging therapies. With the first issue of 2010 of Drug Resistance Updates a change of Editorship will be effectuated and a new Editor-in-Chief has taken over the tasks from Nafsika Georgopapadakou. Nafsika Georgopapadakou is the founding editor of the Journal and has served it since its inception. Helped by her broad knowledge and overview over the fields of infectious diseases and cancer drug development she has built steadily during the past 12 years to a successful publication. Drug Resistance Updates has under her leadership evolved – in times of a continuously changing publishing landscape – into a strong cross-disciplinary medium for highquality reviews, commentaries and perspectives into mechanisms of drug action, drug targets and the inevitable drug resistance. The impact factor of the journal has continued to rise throughout the entire 12-year period, and is currently 9.4, which places it among the top ten journals both in microbiology/infectious diseases and in oncology. The 5-year impact factor of 7.5 clearly documents the success of the journal also in a historic perspective. The new Editor-in-Chief, Dr. Christian G. Giske, is a consultant physician in clinical microbiology, active at Karolinska University Hospital. His research focuses on multidrug resistant Gram-negative bacilli, and he is also heavily involved in antimicrobial susceptibility testing issues, as a member of the steering committee of EUCAST (European Committee on Antimicrobial Susceptibility Testing). The ambition of the new Editor-in-chief is to continue fine-tuning the balance between reviews on antimicro-
1368-7646/$ – see front matter © 2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.drup.2010.01.001
bial and anticancer agents, in the good tradition of the journal. Also, the tradition of presenting promising new treatment concepts will be continued—the journal’s topics will not be limited to drug resistance sensu stricto. Invited reviews will still be the modus operandi of the journal, and with a new editorial board with many excellent scientists we are moving forward with great confidence in the future of the journal. The editorial structure has been revised in January 2010, and the future structure comprises one Editor-inchief, one associate editor and a common editorial board. The new associate editor for Cancer will be Henk Broxterman, the previous section editor for anticancer agents. Indeed, the problems of drug resistance remain a continuous challenge to the scientific, medical and pharmaceutical community in cancer and infectious diseases alike. Therefore it will be the goal of the new editorial team of Drug Resistance Updates – in the tradition of the past years – to critically contribute to the understanding of the mechanisms of drug resistance and novel ways and drug targets to improve treatments. We would like to express gratitude to all contributors, past editorial board members, readers and the publisher for their commitment and continued support. With their support we feel confident that we will successfully meet the challenges ahead. Editor-in-Chief Christian G. Giske Associate Editor Henk J. Broxterman E-mail addresses: [email protected] (C.G. Giske), [email protected] (H.J. Broxterman)
Contents lists available at ScienceDirect
Drug Resistance Updates journal homepage: www.elsevier.com/locate/drup
Editorial
A message from the New Editor-in-Chief Drug Resistance Updates—The past and the future
Twelve years have passed since Drug Resistance Updates was founded. During this period the journal has maintained its original mission: to critically review and analyze chemotherapeutic resistance in infectious diseases and cancer; to integrate recent developments in both basic research and clinical medicine; and to highlight innovative strategies for current and emerging therapies. With the first issue of 2010 of Drug Resistance Updates a change of Editorship will be effectuated and a new Editor-in-Chief has taken over the tasks from Nafsika Georgopapadakou. Nafsika Georgopapadakou is the founding editor of the Journal and has served it since its inception. Helped by her broad knowledge and overview over the fields of infectious diseases and cancer drug development she has built steadily during the past 12 years to a successful publication. Drug Resistance Updates has under her leadership evolved – in times of a continuously changing publishing landscape – into a strong cross-disciplinary medium for highquality reviews, commentaries and perspectives into mechanisms of drug action, drug targets and the inevitable drug resistance. The impact factor of the journal has continued to rise throughout the entire 12-year period, and is currently 9.4, which places it among the top ten journals both in microbiology/infectious diseases and in oncology. The 5-year impact factor of 7.5 clearly documents the success of the journal also in a historic perspective. The new Editor-in-Chief, Dr. Christian G. Giske, is a consultant physician in clinical microbiology, active at Karolinska University Hospital. His research focuses on multidrug resistant Gram-negative bacilli, and he is also heavily involved in antimicrobial susceptibility testing issues, as a member of the steering committee of EUCAST (European Committee on Antimicrobial Susceptibility Testing). The ambition of the new Editor-in-chief is to continue fine-tuning the balance between reviews on antimicro-
1368-7646/$ – see front matter © 2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.drup.2010.01.001
bial and anticancer agents, in the good tradition of the journal. Also, the tradition of presenting promising new treatment concepts will be continued—the journal’s topics will not be limited to drug resistance sensu stricto. Invited reviews will still be the modus operandi of the journal, and with a new editorial board with many excellent scientists we are moving forward with great confidence in the future of the journal. The editorial structure has been revised in January 2010, and the future structure comprises one Editor-inchief, one associate editor and a common editorial board. The new associate editor for Cancer will be Henk Broxterman, the previous section editor for anticancer agents. Indeed, the problems of drug resistance remain a continuous challenge to the scientific, medical and pharmaceutical community in cancer and infectious diseases alike. Therefore it will be the goal of the new editorial team of Drug Resistance Updates – in the tradition of the past years – to critically contribute to the understanding of the mechanisms of drug resistance and novel ways and drug targets to improve treatments. We would like to express gratitude to all contributors, past editorial board members, readers and the publisher for their commitment and continued support. With their support we feel confident that we will successfully meet the challenges ahead. Editor-in-Chief Christian G. Giske Associate Editor Henk J. Broxterman E-mail addresses: [email protected] (C.G. Giske), [email protected] (H.J. Broxterman)